Zealand Pharma A/S
ZLDPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $62,691 | $342,788 | $103,986 | $292,567 |
| % Growth | -81.7% | 229.6% | -64.5% | – |
| Cost of Goods Sold | $7,874 | $19,174 | $30,711 | $118,814 |
| Gross Profit | $54,817 | $323,614 | $73,275 | $173,753 |
| % Margin | 87.4% | 94.4% | 70.5% | 59.4% |
| R&D Expenses | $919,866 | $684,902 | $614,044 | $588,453 |
| G&A Expenses | $160,515 | $73,797 | $274,243 | $260,987 |
| SG&A Expenses | $229,201 | $89,849 | $306,541 | $636,256 |
| Sales & Mktg Exp. | $68,686 | $16,052 | $32,298 | $375,269 |
| Other Operating Expenses | $177,957 | $121,101 | $0 | -$759 |
| Operating Expenses | $1,327,024 | $895,852 | $920,585 | $1,223,950 |
| Operating Income | -$1,272,207 | -$572,238 | -$816,599 | -$1,050,197 |
| % Margin | -2,029.3% | -166.9% | -785.3% | -359% |
| Other Income/Exp. Net | $188,762 | -$136,627 | -$134,888 | $286,468 |
| Pre-Tax Income | -$1,083,445 | -$708,865 | -$972,041 | -$763,729 |
| Tax Expense | -$4,617 | -$5,126 | -$6,431 | -$8,791 |
| Net Income | -$1,078,828 | -$703,739 | -$965,610 | -$1,018,149 |
| % Margin | -1,720.9% | -205.3% | -928.6% | -348% |
| EPS | -16.24 | -12.44 | -20.9 | -23.75 |
| % Growth | -30.5% | 40.5% | 12% | – |
| EPS Diluted | -16.24 | -12.44 | -20.9 | -23.75 |
| Weighted Avg Shares Out | 66,434 | 56,589 | 46,200 | 42,869 |
| Weighted Avg Shares Out Dil | 66,434 | 56,589 | 46,200 | 42,869 |
| Supplemental Information | – | – | – | – |
| Interest Income | $169,639 | $45,324 | $6,542 | $44 |
| Interest Expense | $34,047 | $24,888 | $56,455 | $4,091 |
| Depreciation & Amortization | $25,847 | $25,086 | $30,711 | $25,118 |
| EBITDA | -$1,023,551 | -$657,948 | -$665,262 | -$711,850 |
| % Margin | -1,632.7% | -191.9% | -639.8% | -243.3% |